Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 15;75(14):2800–2810. doi: 10.1158/0008-5472.CAN-14-3041

Figure 5. Immune-independent anti-tumor mechanisms play a key role in FAP-CAR T cell-induced growth inhibition in murine PDA.

Figure 5

(A) Established 4662 tumor-bearing C57BL/6 and NSG mice were treated with FAP-CAR or MigR1 mouse T cells (n=5 per group). A second dose was given 6 days later. * and # denote statistical significance between MigR1 and FAP-CAR-treated samples in B6 and NSG mice, respectively (p value < 0.05). (B) Tumor-bearing KPC mice received FAP-CAR or MigR1 T cells i.v. and tumor progression was followed by ultrasound (n=3 per group). * Denotes statistical significance between MigR1 and FAP-CAR-treated samples, p value < 0.01. The black arrow indicates the time of T cell transfer. 4662 PDAs (C) and autochthonous PDA (D) sections were stained with antibodies against Ki-67 and cleaved caspase-3. * and # denote statistical significance between MigR1 and FAP-CAR T cell-treated samples, p value < 0.01 and p value < 0.05, respectively. Scale: 100 μm.

HHS Vulnerability Disclosure